Dr. Joseph Gabriele
Chief Executive Officer, Chief Science Officer and Director
Dr. Gabriele is the founder, inventor and visionary behind the Delivra™ technology. Dr. Gabriele has devoted the past eight years to innovation, development, and commercialization activities at Delivra, and in addition to providing guidance and vision for Delivra, he actively stewards its robust R&D program. He has a doctorate in molecular pharmacology and is an Assistant Professor (PT), McMaster University, Department of Psychiatry and Behavioral Neurosciences, as well as Special Graduate Faculty, University of Guelph, Department of Biomedical Sciences. Dr. Gabriele received a B.Sc from the University of Toronto, with M.Sc. and Ph.D. degrees from McMaster University. Dr. Gabriele’s Ph.D. training was conducted under Dr. R.K. Mishra, focusing on molecular pharmacology/neuroscience and its implications in psychiatric and neurological disorders. He has received numerous awards, including a CIHR studentship award in pharmacology during his M.Sc. degree; an NSERC Canada Graduate Scholarship during his Ph.D. training; and the International Congress on Schizophrenia Research, Young Investigator Award.
Pascal Attard, CPA, CA
Chief Financial Officer
Mr. Attard has served as the Company’s Chief Financial Officer since August 2018. Mr. Attard joined Delivra in June 2015 as the Company’s Corporate Controller and held the position of Vice-President, Finance from November 2016 to August 2018. Prior to joining Delivra, Pascal was the Corporate Controller for Red Tiger Mining Inc. (TSXV: RMN) from March 2012 to March 2015 and held a number of positions at McGovern Hurley LLP from January 2006 to March 2012, where he most recently served as Manager, Audit and Assurance. Mr. Attard holds a Bachelor of Accountancy, with honours, from Brock University and holds a Chartered Accountant and a Chartered Professional Accountant designation.
Dr. David Baranowski
Director of Research
Dr. Baranowski joined the company at the inception of its research and development laboratory in 2013. He manages the day-to-day operations of the R&D segment of Delivra, guiding and designing basic, pre-clinical, and clinical research with a strong focus on the regulatory pathways to product development. Dr. Baranowski also functions as human resource manager of R&D and holds an Adjunct Professor position at the University of Prince Edward Island. Dr. Baranowski has worked in the biotechnology industry for 10 years as a research scientist for various enterprises including CRP40 Inc. and Neurodyn Inc. with experience in laboratory management, methods development, and pre-clinical experimentation. His previous position as a research scientist included technical expertise associated therapeutics and diagnostics for Parkinson’s disease along with numerous bioanalytical methods and synthetic chemistry. Dr. Baranowski received his Ph.D. at McGill University investigating the in vivo function of progranulin and proprotein convertase subtilisin/kexin type 9 (PCSK9), proteins involved in dementia and wound healing and cholesterol and lipid metabolism, respectively. At present Dr. Baranowski oversees the execution of Delivra’s R&D overarching mission, to translate research from benchtop to kitchen counter.